<DOC>
	<DOCNO>NCT02686138</DOCNO>
	<brief_summary>This phase 3 , 26-week , randomize , double-blind , placebo-controlled , multi-center study evaluate safety efficacy one dose Tenapanor subject constipation-predominant irritable bowel syndrome ( IBS-C ) define ROME III criterion active disease determine two-week screening period . Subjects qualify randomize study either receive 50mg BID Tenapanor ( 1:1 ) 26 week treatment period .</brief_summary>
	<brief_title>A 26-Week Study Evaluate Efficacy Safety Tenapanor IBS-C</brief_title>
	<detailed_description>During 26-week double-blind treatment period , subject record daily assessment include : frequency time bowel movement ; sensation complete bowel emptying ; consistency bowel movement ; degree straining , worst abdominal pain , abdominal discomfort , abdominal bloating , abdominal fullness abdominal cramping ; use timing rescue medication . Subjects also record weekly assessment include : adequate relief IBS symptom , degree relief IBS symptom , IBS severity , constipation severity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Males female age 18 75 year , inclusive Females must nonchildbearing potential ; If childbearing potential , must negative pregnancy test confirm use one appropriate mean contraception Males must agree use appropriate method barrier contraception document surgical sterilization Subject meet definition IBSC use Rome III Criteria Diagnosis IBS A colonoscopy base AGA guideline ; every 10 year â‰¥50 year old Functional diarrhea define Rome III criterion IBS diarrhea ( IBSD ) , mixed IBS ( IBSM ) , unsubtyped IBS define Rome III criterion Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract within 6 month prior screen , active disease within 6 month prior screen ; include limited cancer , inflammatory bowel disease , diverticulitis , duodenal ulcer , erosive esophagitis , gastric ulcer , pancreatitis ( within 12 month screen ) , cholelithiasis , amyloidosis , ileus , noncontrolled GERD , gastrointestinal obstruction carcinoid syndrome . Potential CNS cause constipation ( e.g. , Parkinson 's disease , spinal cord injury , multiple sclerosis ) Subject history current evidence laxative abuse ( clinical judgment physician ) Hepatic dysfunction ( ALT [ SGPT ] AST [ SGOT ] &gt; 2.5 time upper limit normal ) renal impairment ( serum creatinine &gt; 2 mg/dL ) Any evidence treatment malignancy ( localize basal cell , squamous cell skin cancer cancer situ resect ) within previous year Any surgery stomach , small intestine colon , exclude appendectomy cholecystectomy ( unless within 60 day screen visit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>